Heparin Braun (Heparin Sodium)

Heparin Braun is indicated for several anticoagulation purposes in medical practice. It is employed to:

• Prevent clot formation during cardiac surgery and extracorporeal circulation.
• Treat acute deep vein thrombosis and pulmonary embolism.
• Maintain catheter patency in hemodialysis and other vascular access procedures.
• Manage acute coronary syndromes when rapid anticoagulation is required.
• Provide prophylaxis against venous thromboembolism in high‑risk postoperative patients.

Side effects of Heparin Braun vary in frequency and severity. Common adverse reactions are usually mild and reversible, while serious events are less frequent but require immediate attention.

Common

• Minor bleeding at injection site.
• Small bruising or hematoma formation.
• Transient elevation of liver enzymes.
• Mild thrombocytopenia.
• Nausea or mild gastrointestinal discomfort.

Serious

• Major hemorrhage (intracranial, gastrointestinal, or surgical).
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clotting.
• Severe allergic reactions, including anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Acute renal impairment in rare cases.

When using Heparin Braun, clinicians should observe several safety measures to minimize risk. Important precautions include:

• Assess baseline coagulation status and platelet count before initiation.
• Adjust dosage in patients with renal or hepatic impairment.
• Avoid use in individuals with a history of heparin‑induced thrombocytopenia.
• Monitor for signs of bleeding, especially in surgical or trauma patients.
• Use caution in pregnant or lactating women, weighing maternal benefits against fetal risk.
• Ensure proper storage conditions to maintain product stability.

Heparin Braun may interact with various medications, influencing its anticoagulant effect or increasing bleeding risk. Interaction guidance is grouped for clarity.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without specialist supervision.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and high‑dose aspirin, which can potentiate bleeding.
• Thrombolytic agents such as alteplase or streptokinase.

Use with caution

• Antiplatelet agents (e.g., clopidogrel, ticagrelor) – monitor for additive bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) – may increase gastrointestinal bleeding.
• Glycoprotein IIb/IIIa inhibitors – heightened hemorrhagic risk.
• Certain antibiotics (e.g., vancomycin) that can affect platelet function.